News
TEVA
17.43
-7.14%
-1.34
It seems like you've provided a financial report document, specifically a 10-Q filing, which is a quarterly report filed by publicly traded companies with the Securities and Exchange Commission (SEC). Since there is no article title provided, I'll assume you'd like me to generate a title based on the content. However, without the actual content, it's challenging to create a meaningful title. If you could provide more context or the actual content of the 10-Q filing, I'd be happy to help you generate a title. Alternatively, if you'd like to provide a brief summary of the article, I can try to create a title for you.
Press release · 2h ago
SA Asks: How will the U.S. election results impact healthcare stocks?
Seeking Alpha · 7h ago
Trump Media, broader market surge after Trump wins election: Morning Buzz
TipRanks · 10h ago
Teva Pharmaceutical Industries (TEVA) Q3 2024 Earnings Call Transcript
The Motley Fool · 11h ago
Generic Drug Maker Teva Clocks 13% Jump In Q3 Revenues, Tightens Annual Forecast
Benzinga · 12h ago
BUZZ-Teva Pharma's US-listed shares up after lifting 2024 forecast, upbeat Q3 results
Reuters · 13h ago
Teva Pharmaceutical CEO Francis Says Expects Generics Prices To Be Pushed Down In 2025
Benzinga · 14h ago
Teva sees FY24 adjusted EBITDA $4.7B-$5B
TipRanks · 14h ago
Teva gains after raising outlook for second time this year
Seeking Alpha · 14h ago
UPDATE 1-Teva Pharmaceutical raises 2024 outlook as Q3 profit beats estimates
Reuters · 15h ago
UPDATE 2-Teva Pharmaceutical sees more growth in 2025 after strong Q3
Reuters · 15h ago
Teva Pharmaceutical third-quarter profit, revenue top estimates
Reuters · 15h ago
Teva reports Q3 EPS 69c, consensus 66c
TipRanks · 15h ago
Teva sees FY24 EPS $2.40-$2.50, consensus $2.45
TipRanks · 15h ago
Teva Forecasts 2024 Adjusted EPS Of $2.40-$2.50 Versus Prior Guidance Of $2.30-$2.50 And Consensus Of $2.45
Benzinga · 15h ago
Teva Pharmaceutical beats Q3 top and bottom line estimates
Seeking Alpha · 15h ago
Teva Pharmaceutical Indus Q3 2024 Adj EPS $0.69 Beats $0.66 Estimate, Sales $4.33B Beat $4.12B Estimate
Benzinga · 15h ago
TEVA ANNOUNCES STRONG FINANCIAL RESULTS FOR THE THIRD QUARTER OF 2024, LED BY GENERICS PERFORMANCE AND INNOVATIVE PORTFOLIO GROWTH; RAISES 2024 FINANCIAL OUTLOOK INCLUDING ON REVENUES, ADJUSTED EBITDA AND NON-GAAP EPS
Reuters · 16h ago
Teva Pharmaceutical Industries Q3 24 Earnings Conference Call At 8:00 AM ET
NASDAQ · 16h ago
Barclays Reaffirms Their Buy Rating on Teva Pharmaceutical (TEVA)
TipRanks · 19h ago
More
Webull provides a variety of real-time TEVA stock news. You can receive the latest news about Teva Pharm through multiple platforms. This information may help you make smarter investment decisions.
About TEVA
Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.